South Dakota Investment Council Boosts Holdings in Omnicell, Inc. (NASDAQ:OMCL)

South Dakota Investment Council increased its holdings in Omnicell, Inc. (NASDAQ:OMCL) by 14.8% in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 21,727 shares of the company’s stock after purchasing an additional 2,800 shares during the period. South Dakota Investment Council’s holdings in Omnicell were worth $818,000 as of its most recent SEC filing.

Other large investors also recently added to or reduced their stakes in the company. Avory & Company LLC increased its stake in shares of Omnicell by 22.7% in the third quarter. Avory & Company LLC now owns 153,776 shares of the company’s stock worth $6,926,000 after buying an additional 28,416 shares during the period. Vanguard Group Inc. grew its stake in shares of Omnicell by 15.1% in the third quarter. Vanguard Group Inc. now owns 5,137,084 shares of the company’s stock worth $231,374,000 after purchasing an additional 674,824 shares during the last quarter. Pacer Advisors Inc. increased its holdings in Omnicell by 321,488.8% during the 4th quarter. Pacer Advisors Inc. now owns 1,058,027 shares of the company’s stock valued at $39,814,000 after purchasing an additional 1,057,698 shares during the period. Public Sector Pension Investment Board bought a new position in Omnicell during the 3rd quarter valued at approximately $2,517,000. Finally, Ontario Teachers Pension Plan Board purchased a new stake in Omnicell in the third quarter worth about $984,000. Hedge funds and other institutional investors own 97.70% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on OMCL. Wells Fargo & Company lowered their target price on shares of Omnicell from $28.00 to $26.00 and set an “equal weight” rating for the company in a report on Friday, February 9th. Barclays started coverage on shares of Omnicell in a research report on Wednesday, January 3rd. They set an “underweight” rating and a $33.00 price objective for the company. Finally, Benchmark lowered their price target on shares of Omnicell from $42.00 to $38.00 and set a “buy” rating on the stock in a report on Friday, February 9th. One analyst has rated the stock with a sell rating, three have issued a hold rating and three have given a buy rating to the company. According to MarketBeat, Omnicell has a consensus rating of “Hold” and a consensus price target of $42.20.

Omnicell Stock Down 1.1 %

Shares of OMCL opened at $27.13 on Friday. The company’s fifty day moving average price is $27.68 and its 200-day moving average price is $32.44. Omnicell, Inc. has a 1-year low of $25.69 and a 1-year high of $77.14. The company has a debt-to-equity ratio of 0.48, a current ratio of 2.52 and a quick ratio of 2.22.

Omnicell (NASDAQ:OMCL) last posted its earnings results on Thursday, February 8th. The company reported $0.12 EPS for the quarter, topping the consensus estimate of ($0.10) by $0.22. The firm had revenue of $258.85 million for the quarter, compared to analyst estimates of $256.00 million. Omnicell had a positive return on equity of 3.43% and a negative net margin of 1.78%. Sell-side analysts anticipate that Omnicell, Inc. will post 0.09 EPS for the current year.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.